New drugs for weight loss: Why change in body composition matters and why nutrition and exercise remain paramount.
Can Fam Physician · 2025
Last updated 2026-05-28New weight-loss drugs like semaglutide and tirzepatide are recommended for adults with obesity or overweight with related health issues, but long-term use may be needed. These drugs can reduce weight in children and adolescents, though long-term effects are unknown, and they may be harmful for elderly patients. Weight loss from any method can reduce muscle and bone, so nutrition (like protein supplements) and exercise (especially resistance training) are important to protect these tissues. Stopping the drugs or using them for small weight loss may lead to regaining weight, often as fat, which could worsen obesity over time.
AI summary of the abstract below.
| Journal | Can Fam Physician, 2025 |
|---|---|
| Citations | 0 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
OBJECTIVE: To identify patients who may or may not benefit from use of new drugs for weight loss and to aid in minimizing loss of lean mass through proactive nutrition and exercise interventions.
QUALITY OF EVIDENCE: Choices and interventions are evaluated using the Grading of Recommendations Assessment, Development and Evaluation framework. Quality varies widely and is documented in multiple tables.
MAIN MESSAGE: Semaglutide and tirzepatide should be used in patients living with obesity or with overweight accompanied by weight-related comorbidity. Long-term use may be necessary. Use in children and adolescents has proven effective for weight reduction, but long-term consequences are unknown. Use in elderly patients may be harmful. Because weight loss by any means is accompanied by loss of lean mass, specifically muscle and bone, particular attention must be paid to nutrition and exercise. Protein supplementation is effective to preserve muscle mass. Resistance training is effective in mitigation of both muscle and bone loss. Both resistance and aerobic training are beneficial in preventing osteopenia in weight loss, which may contribute to premature mortality. There is observational evidence that weight cycling may be harmful in that weight regain can be composed primarily of fat, multiple cycles of which may actually increase obesity in individuals. This is of particular concern because of the cost and limited availability of new weight loss drugs leading to large rates of discontinuation. Similarly, patients using drugs for small amounts of weight loss are likely to regain or overshoot if they discontinue.
CONCLUSION: Patient selection for use of new anti-obesity drugs should match those included in clinical trials and be paired with dietary and exercise interventions used in those trials. Use at the extremes of age is problematic because of lack of long-term data. Intermittent use for small amounts of weight loss may be harmful. More ongoing data are needed.
Verbatim abstract via PubMed 41285626 ↗